Generic clopidogrel–the medicines agency’s perspective
Journal Title: Generics and Biosimilars Initiative Journal - Year 2012, Vol 1, Issue 2
Abstract
A number of generic products containing clopidogrel as the active substance have been marketed in Austria and the EU for some time. Due to different clopidogrel salt preparations and different indications, doubts arose as to whether the products could be considered as equivalent. The Austrian Federal Office for Safety in Health Care (BASG)/The Austrian Agency for Health and Food Safety (AGES PharmMed) considered this issue and reached the conclusion that the generic clopidogrel products were in principle equivalent to the originator product with regard to safety and efficacy.
Authors and Affiliations
Christoph Baumgärtel
Keywords
Related Articles
- EP ID EP355165
- DOI 10.5639/gabij.2012.0102.019
- Views 97
- Downloads 0
Biosimilars naming and prescribing policy in Australia
To the Editor: I wanted to bring to your attention the following paper which was published in Volume 2/Year 2013/Issue 3 of the Generics and Biosimilars Initiative Journal. The Perspective paper titled Licensing and pr...
How matrix models can support generic medicine prescribing
This paper describes the design of currently available matrix models and assesses the experience with these models to date. Matrix models provide a valuable tool to facilitate transparent and interactive evidence-based m...
Innovator companies should focus on innovations
Despite biopharmaceuticals having an enormous potential value for our health, they have also become a serious threat to our healthcare systems.
A patient-centred paradigm for the biosimilars market
The advent of similar biological medicinal products or ‘biosimilars’ in Europe in the 2000s has led to development of a global biosimilars market and regulatory frameworks designed specifically for approval of biosimilar...
First Asia-Pacific educational workshop on non-biological complex drugs (NBCDs), Kuala Lumpur, Malaysia, 8 October 2013
Introduction: In recent years a new category of medicinal products, the non-biological complex drugs (NBCDs) emerged. They are distinct from both the small molecules and the biological therapeutics by being composed of n...